Compare Consolidated Edison, Inc. (ED) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Consolidated Edison (ED) trades at $109.60, up 2.24% with a bullish technical signal. The stock shows strong fundamentals with $16.92B revenue, 12.53% net margin, and consistent dividend payments. Recent earnings show mixed results with Q2 beat but Q1 miss. The company maintains solid cash flow generation of $4.8B from operations in 2025 while investing heavily in infrastructure.

ED presents a stable utility investment with moderate growth and reliable dividends, though analyst consensus leans heavily toward Hold (63%). Key risks include regulatory pressures and capital-intensive infrastructure demands. The current price sits above the $105.56 consensus target, suggesting limited near-term upside despite positive economic impact from New York operations.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.